HER2 breast cancer therapies: a review

References

• FriedlanderEBarokMSzollosiJVerebGErbB-directed immunotherapy: antibodies in current practice and promising new agentsImmunol Lett2008116212614018201769
   PubMed Web of Science ®Google Scholar
• SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience198723547851771823798106
   PubMed Web of Science ®Google Scholar
• SlamonDJGodolphinWJonesLAStudies of the HER- 2/neu proto-oncogene in human breast and ovarian cancerScience198924449057077122470152
   PubMed Web of Science ®Google Scholar
• SeshadriRFirgairaFAHorsfallDJMcCaulKSetlurVKitchenPClinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study GroupJ Clin Oncol19931110193619428105035
   PubMed Web of Science ®Google Scholar
• TandonAKClarkGMChamnessGCUllrichAMcGuireWLHER- 2/neu oncogene protein and prognosis in breast cancerJ Clin Oncol198978112011282569032
   PubMed Web of Science ®Google Scholar
• FendlyBMWingetMHudziakRMLipariMTNapierMAUllrichACharacterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene productCancer Res1990505155015581689212
   PubMed Web of Science ®Google Scholar
• CarterPPrestaLGormanCMHumanization of an anti-p185HER2 antibody for human cancer therapyProc Natl Acad Sci U S A19928910428542891350088
   PubMed Web of Science ®Google Scholar
• CooleySBurnsLJRepkaTMillerJSNatural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neuExp Hematol199927101533154110517495
   PubMed Web of Science ®Google Scholar
• AlbanellJCodonyJRoviraAMelladoBGasconPMechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4Adv Exp Med Biol200353225326812908564
   PubMed Web of Science ®Google Scholar
• IzumiYXuLdi TomasoEFukumuraDJainRKTumour biology: herceptin acts as an anti-angiogenic cocktailNature2002416687827928011907566
   PubMed Web of Science ®Google Scholar
• BaselgaJAlbanellJMolinaMAArribasJMechanism of action of trastuzumab and scientific updateSemin Oncol2001285 Suppl 1641111706390
   PubMed Web of Science ®Google Scholar
• AustinCDDe MaziereAMPisacanePIEndocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycinMol Biol Cell200415125268528215385631
   PubMed Web of Science ®Google Scholar
• BaselgaJTripathyDMendelsohnJPhase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing meta-static breast cancerJ Clin Oncol19961437377448622019
   PubMed Web of Science ®Google Scholar
• CobleighMAVogelCLTripathyDMultinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic diseaseJ Clin Oncol19991792639264810561337
   PubMed Web of Science ®Google Scholar
• VogelCLCobleighMATripathyDEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancerJ Clin Oncol200220371972611821453
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• MartyMCognettiFMaraninchiDRandomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupJ Clin Oncol200523194265427415911866
   PubMed Web of Science ®Google Scholar
• EstevaFJValeroVBooserDPhase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancerJ Clin Oncol20022071800180811919237
   PubMed Web of Science ®Google Scholar
• SeidmanADFornierMNEstevaFJWeekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificationJ Clin Oncol200119102587259511352950
   PubMed Web of Science ®Google Scholar
• BursteinHJHarrisLNMarcomPKTrastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithmJ Clin Oncol200321152889289512885806
   PubMed Web of Science ®Google Scholar
• BartschRWenzelCAltorjaiGCapecitabine and trastuzumab in heavily pretreated metastatic breast cancerJ Clin Oncol200725253853385817679724
   PubMed Web of Science ®Google Scholar
• SchallerGFuchsIGonschTPhase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanesJ Clin Oncol200725223246325017577021
   PubMed Web of Science ®Google Scholar
• YamamotoDIwaseSKitamuraKOdagiriHYamamotoCNagumoYA phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 TrialCancer Chemother Pharmacol200861350951417516068
   PubMed Web of Science ®Google Scholar
• PegramMDLiptonAHayesDFPhase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/ neu monoclonal antibody plus cisplatin in patients with HER2/ neuoverexpressing metastatic breast cancer refractory to chemotherapy treatmentJ Clin Oncol1998168265926719704716
   PubMed Web of Science ®Google Scholar
• PegramMDPienkowskiTNorthfeltDWResults of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancerJ Natl Cancer Inst2004961075976915150304
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJAVukeljaSMarslandTKimmelGRatnamSPippenJEPhase II study of trastuzumab plus gemcitabine in chemotherapy- pretreated patients with metastatic breast cancerClin Breast Cancer20045214214715245619
   PubMedGoogle Scholar
• Von MinckwitzGZielinskiCMaarteenseECapecitabine vs capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05)J Clin Oncol200826May 20 Suppl abstr 1025
   Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med2005353161659167216236737
   PubMed Web of Science ®Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med2005353161673168416236738
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNPhase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2/neu positive early breast cancer patients: BCIRG 006 StudySan Antonio Breast Cancer Symposium2005 abstr 1
   Google Scholar
• JoensuuHKellokumpu-LehtinenPLBonoPAdjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancerN Engl J Med2006354880982016495393
   PubMed Web of Science ®Google Scholar
• SpielmannMRochéHHumbletY3-year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2- positive breast cancer patients: results of the PACS-04 trialSan Antonio Breast Cancer Symposium2007 (abstr 72)
   Google Scholar
• SmithIProcterMGelberRD2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialLancet200736995552936
   Web of Science ®Google Scholar
• SlamonDEiermannWRobertNBCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patientsBreast Cancer Res Treat2006106Suppl 152a
   Google Scholar
• Six vs 12 months of transtuzumab with docetaxel following FEC as adjuvant treatment in N+ breast cancerAccessed online 23 January 2009 http://clinicaltrials.gov/ct2/show/NCT00615602
   Google Scholar
• Trastuzumab for 6 months or 1 year in treating women with nonmeta-static breast cancer that can be removed by surgeryAccessed online 27th April 2009 http://www.clinicaltrials.gov/ct2/show/NCT00381901
   Google Scholar
• TelliMLHuntSACarlsonRWGuardinoAETrastuzumab-related cardiotoxicity: calling into question the concept of reversibilityJ Clin Oncol200725233525353317687157
   PubMed Web of Science ®Google Scholar
• Tan-ChiuEYothersGRomondEAssessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31J Clin Oncol200523317811781916258083
   PubMed Web of Science ®Google Scholar
• EwerMSVooletichMTDurandJBReversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatmentJ Clin Oncol200523317820782616258084
   PubMed Web of Science ®Google Scholar
• ChenBPengXPentassugliaLLimCCSawyerDBMolecular and cellular mechanisms of anthracycline cardiotoxicityCardiovasc Toxicol20077211412117652815
   PubMed Web of Science ®Google Scholar
• Trastuzumab FDA label (version approved on 01/18/2008)Accessed online 04/27/2009 Available at http://www.fda.gov/cder/foi/label/2008/103792s5175lbl.pdf2008
   Google Scholar
• NahtaREstevaFJHER2 therapy: molecular mechanisms of trastuzumab resistanceBreast Cancer Res20068621517096862
   PubMed Web of Science ®Google Scholar
• ScaltritiMRojoFOcanaAExpression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancerJ Natl Cancer Inst200799862863817440164
   PubMed Web of Science ®Google Scholar
• RitterCAPerez-TorresMRinehartCHuman breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor networkClin Cancer Res200713164909491917699871
   PubMed Web of Science ®Google Scholar
• NagataYLanKHZhouXPTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell20046211712715324695
   PubMed Web of Science ®Google Scholar
• ClarkASWestKStreicherSDennisPAConstitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cellsMol Cancer Ther20021970771712479367
   PubMed Web of Science ®Google Scholar
• NahtaRTakahashiTUenoNTHungMCEstevaFJP27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cellsCancer Res200464113981398615173011
   PubMed Web of Science ®Google Scholar
• Vazquez-MartinAColomerRBrunetJMenendezJAPharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting ‘HER2 super-expression’ occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cellsInt J Oncol200731476977617786307
   PubMed Web of Science ®Google Scholar
• RusnakDWLackeyKAffleckKThe effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivoMol Cancer Ther200112859412467226
   PubMed Web of Science ®Google Scholar
• XiaWLiuLHHoPSpectorNLTruncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016Oncogene200423364665314737100
   PubMed Web of Science ®Google Scholar
• XiaWGerardCMLiuLBaudsonNMOryTLSpectorNLCombining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cellsOncogene200524416213622116091755
   PubMed Web of Science ®Google Scholar
• KonecnyGEPegramMDVenkatesanNActivity of the dual kinase inhibitor lapatinib (GW572016) against HER- 2-overexpressing and trastuzumab-treated breast cancer cellsCancer Res20066631630163916452222
   PubMed Web of Science ®Google Scholar
• XiaWMullinRJKeithBRAnti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathwaysOncogene200221416255626312214266
   PubMed Web of Science ®Google Scholar
• BenceAKAndersonEBHalepotaMAPhase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjectsInvest New Drugs2005231394915528979
   PubMed Web of Science ®Google Scholar
• VersolaMBurrisHJonesSClinical activity of GW572016 in EGF10003 in patients with solid tumorsJ Clin Oncol20042214S July 15 Suppl3047
   Google Scholar
• BurrisHTaylorCJonesSA phase I study of GW572016 in patients with solid tumorsProc Am Soc Clin Oncol200322 abstr 994
   Google Scholar
• PanditeLBurrisHJonesSA safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumorsJ Clin Oncol20042214S July 15 Suppl3179
   Google Scholar
• BurrisHA3rdHurwitzHIDeesECPhase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomasJ Clin Oncol200523235305531315955900
   PubMed Web of Science ®Google Scholar
• BursteinHJStornioloAMFrancoSA phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancerAnn Oncol20081961068107418283035
   PubMed Web of Science ®Google Scholar
• BlackwellKLPegramMDTan-ChiuESingle-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimensAnn Oncol20092929
   Google Scholar
• GomezHLDovalDCChavezMAEfficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancerJ Clin Oncol200826182999300518458039
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med2006355262733274317192538
   PubMed Web of Science ®Google Scholar
• CameronDCaseyMPressMA phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesBreast Cancer Res Treat2008112353354318188694
   PubMed Web of Science ®Google Scholar
• Di LeoAGomezHLAzizZPhase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancerJ Clin Oncol200826345544555218955454
   PubMed Web of Science ®Google Scholar
• KurokawaHArteagaCLInhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancerClin Cancer Res2001712 Suppl4436s4442s discussion 4411s–4412s11916237
   PubMed Web of Science ®Google Scholar
• JohnstonSPegramMPressMLapatinib combined with letrozole vs letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 TrialSan Antonio Breast Cancer Symposium2008 abstr 46
   Google Scholar
• MackeyJKaufmanBClemensMTrastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancerBreast Cancer Res Treat2006100Suppl 1 abstr 3
   Google Scholar
• O’ShaughnessyJBlackwellKLBursteinHA randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2 + metastatic breast cancer progressing on trastuzumab therapyJ Clin Oncol200826May 20 Suppl abstr 1015
   Google Scholar
• BendellJCDomchekSMBursteinHJCentral nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinomaCancer200397122972297712784331
   PubMed Web of Science ®Google Scholar
• GrilBPalmieriDBronderJLEffect of lapatinib on the out-growth of metastatic breast cancer cells to the brainJ Natl Cancer Inst2008100151092110318664652
   PubMedGoogle Scholar
• GuarneriVFrassoldatiABruzziPMulticentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278)Clin Breast Cancer20088545345618952561
   PubMed Web of Science ®Google Scholar
• TomaselloGde AzambujaEDinhPSnojNPiccart-GebhartMJumping higher: is it still possible? The ALTTO trial challengeExpert Rev Anticancer Ther20088121883189019046108
   PubMed Web of Science ®Google Scholar
• DangCLinNMoyBDose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated resultsSan Antonio Breast Cancer Symposium2008 abstr 2108
   Google Scholar
• SchneiderCSepp-LorenzinoLNimmesgernEPharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90Proc Natl Acad Sci U S A1996932514536145418962087
   PubMed Web of Science ®Google Scholar
• SolitDBRosenNHsp90: a novel target for cancer therapyCurr Top Med Chem20066111205121416842157
   PubMed Web of Science ®Google Scholar
• MaloneyAWorkmanPHSP90 as a new therapeutic target for cancer therapy: the story unfoldsExpert Opin Biol Ther20022132411772336
   PubMed Web of Science ®Google Scholar
• BassoADSolitDBMunsterPNRosenNAnsamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2Oncogene20022181159116611850835
   PubMed Web of Science ®Google Scholar
• SolitDBZhengFFDrobnjakM17-Allylamino-17-demethoxygel-danamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenograftsClin Cancer Res20028598699312006510
   PubMed Web of Science ®Google Scholar
• BanerjiUO’DonnellAScurrMPhase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignanciesJ Clin Oncol200523184152416115961763
   PubMed Web of Science ®Google Scholar
• GoetzMPToftDReidJPhase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancerJ Clin Oncol20052361078108715718306
   PubMed Web of Science ®Google Scholar
• GremJLMorrisonGGuoXDPhase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumorsJ Clin Oncol20052391885189315774780
   PubMed Web of Science ®Google Scholar
• NowakowskiGSMcCollumAKAmesMMA phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancerClin Cancer Res20061220 Pt 16087609317062684
   PubMed Web of Science ®Google Scholar
• RamanathanRKEgorinMJEisemanJLPhase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancersClin Cancer Res20071361769177417363531
   PubMed Web of Science ®Google Scholar
• RamanathanRKTrumpDLEisemanJLPhase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancersClin Cancer Res20051193385339115867239
   PubMed Web of Science ®Google Scholar
• SolitDBIvySPKopilCPhase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancerClin Cancer Res20071361775178217363532
   PubMed Web of Science ®Google Scholar
• ModiSStopeckATGordonMSCombination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation studyJ Clin Oncol200725345410541718048823
   PubMed Web of Science ®Google Scholar
• ModiSSugarmanSStopeckAPhase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)J Clin Oncol200826May 20 Suppl abstr 1027
   Google Scholar
• FranklinMCCareyKDVajdosFFLeahyDJde VosAMSliwkowskiMXInsights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell20045431732815093539
   PubMed Web of Science ®Google Scholar
• GelmonKAFumoleauPVermaSResults of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapyJ Clin Oncol200826May 20 suppl abstr 1026
   Google Scholar
• SlamonDJProto-oncogenes and human cancersN Engl J Med1987317159559573627214
   PubMed Web of Science ®Google Scholar
• Lewis PhillipsGDLiGDuggerDLTargeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateCancer Res200868229280929019010901
   PubMed Web of Science ®Google Scholar
• BeeramMKropIModiSA phase I study of trastuzumab- MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2 + metastatic breast cancer (BC)J Clin Oncol20072518S June 20 Suppl abstr 1042
   Google Scholar
• KropIEMitaMBurrisHAA phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+ breast cancerSan Antonio Breast Cancer Symposium2008 (abstr 3136)
   Google Scholar
• VukeljaSRugoHVogelCA phase II study of trastuzumab- DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancerSan Antonio Breast Cancer Symposium2008 abstr 33
   Google Scholar
• BursteinHJSunYTanARNeratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancerSan Antonio Breast Cancer Symposium2008 abstr 37
   Google Scholar
• BernsKHorlingsHMHennessyBTA functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerCancer Cell10200712439540217936563
   PubMed Web of Science ®Google Scholar
• O’ReganRAndreFCamponeMRAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase I clinical trialSan Antonio Breast Cancer Symposium2008 abstr 3119
   Google Scholar
• FasoloAGianniLRoriveAMulticenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumabSan Antonio Breast Cancer Symposium2008
   Google Scholar